Zealand announces successful EndofPhase 2 meeting with FDA on glepaglutide for short bowel syndrome

Company announcement No. 122018 Zealand announces successful EndofPhase 2 meeting with FDA on glepaglutide for short bowel syndrome Glepaglutide is in development as a new treatment option for patients with short bowel syndrome The pivotal phase...